Angioedemas, Hereditary Concept

subject area of

• A Core Outcome Set for Efficacy of Acute Treatment of Hereditary Angioedema  Journal Articles
• Canadian physician survey on the medical management of hereditary angioedema  Journal Articles
• Current Status of Implementation of Self-Administration Training in Various Regions of Europe, Canada and the USA in the Management of Hereditary Angioedema  Conferences
• Demographic and clinical characteristics of patients with hereditary angioedema in Canada  Journal Articles
• Development of the Hereditary Angioedema Rapid Triage Tool  Journal Articles
• Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters  Journal Articles
• Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension study  Journal Articles
• Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema  Journal Articles
• Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema  Journal Articles
• How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both  Journal Articles
• International Consensus on the Use of Genetics in the Management of Hereditary Angioedema  Journal Articles
• Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks  Journal Articles
• Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study  Journal Articles
• Population pharmacokinetics of subcutaneous C1‐inhibitor for prevention of attacks in patients with hereditary angioedema  Journal Articles
• Prolonging the circulatory half-life of C1 esterase inhibitor via albumin fusion.  Journal Articles
• Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial  Journal Articles
• Quality of life in patients with hereditary angioedema in Canada  Journal Articles
• The thrombogenicity of C1 esterase inhibitor (human): Review of the evidence  Journal Articles